{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:58:58Z","timestamp":1783033138458,"version":"3.54.6"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10354-020-00810-w","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T10:21:37Z","timestamp":1611915697000},"page":"120-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New therapeutic options for bone diseases","Neue therapeutische Optionen f\u00fcr Knochenerkrankungen"],"prefix":"10.1007","volume":"171","author":[{"given":"Roland","family":"Kocijan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Haschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Feurstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Zwerina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"810_CR1","series-title":"Handbook of experimental pharmacology","volume-title":"Osteoporosis therapeutics 2020","author":"R Kocijan","year":"2020","unstructured":"Kocijan\u00a0R, Klaushofer\u00a0K, Misof\u00a0BM. Osteoporosis therapeutics 2020. Handbook of experimental pharmacology. 2020."},{"issue":"1","key":"810_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi\u00a0D, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a\u00a0sclerostin monoclonal antibody. J\u00a0Bone Miner Res. 2011;26(1):19\u201326.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"810_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald\u00a0BT, Tamai\u00a0K, He\u00a0X. Wnt\/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9\u201326.","journal-title":"Dev Cell"},{"issue":"3","key":"810_CR4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow\u00a0ME, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a\u00a0novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577\u201389.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"810_CR5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung\u00a0MR, et\u00a0al. Romosozumab in postmenopausal women with low bone mineral density. N\u00a0Engl J Med. 2014;370(5):412\u201320.","journal-title":"N Engl J Med"},{"issue":"16","key":"810_CR6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman\u00a0F, et\u00a0al. Romosozumab treatment in postmenopausal women with osteoporosis. N\u00a0Engl J Med. 2016;375(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"8","key":"810_CR7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman\u00a0F, et\u00a0al. Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J\u00a0Bone Miner Res. 2018;33(8):1407\u201316.","journal-title":"J Bone Miner Res"},{"issue":"15","key":"810_CR8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag\u00a0KG, et\u00a0al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N\u00a0Engl J Med. 2017;377(15):1417\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"810_CR9","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki\u00a0EM, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J\u00a0Clin Endocrinol Metab. 2018;103(9):3183\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"810_CR10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi\u00a0A, et\u00a0al. Increased bone mineral density for 1\u00a0year of romosozumab, vs placebo, followed by 2\u00a0years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019;14(1):59.","journal-title":"Arch Osteoporos"},{"issue":"3","key":"810_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki\u00a0EM, et\u00a0al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J\u00a0Bone Miner Res. 2019;34(3):419\u201328.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"810_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.afos.2018.03.002","volume":"4","author":"MR McClung","year":"2018","unstructured":"McClung\u00a0MR. Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia. 2018;4(1):11\u20135.","journal-title":"Osteoporos Sarcopenia"},{"key":"810_CR13","doi-asserted-by":"crossref","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina\u00a0K, et\u00a0al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone. 2020;140:115574.","journal-title":"Bone"},{"issue":"10102","key":"810_CR14","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl\u00a0BL, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a\u00a0randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585\u201394.","journal-title":"Lancet"},{"issue":"549","key":"810_CR15","doi-asserted-by":"publisher","first-page":"eaay6570","DOI":"10.1126\/scitranslmed.aay6570","volume":"12","author":"J Bovijn","year":"2020","unstructured":"Bovijn\u00a0J, et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. 2020;12(549):eaay6570. https:\/\/doi.org\/10.1126\/scitranslmed.aay6570.","journal-title":"Sci Transl Med"},{"issue":"1","key":"810_CR16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","volume":"28","author":"BP Sinder","year":"2013","unstructured":"Sinder\u00a0BP, et\u00a0al. Sclerostin antibody improves skeletal parameters in a\u00a0Brtl\/+ mouse model of osteogenesis imperfecta. J\u00a0Bone Miner Res. 2013;28(1):73\u201380.","journal-title":"J Bone Miner Res"},{"key":"810_CR17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","volume":"71","author":"BP Sinder","year":"2015","unstructured":"Sinder\u00a0BP, et\u00a0al. Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone. 2015;71:115\u201323.","journal-title":"Bone"},{"issue":"8","key":"810_CR18","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","volume":"25","author":"BP Sinder","year":"2014","unstructured":"Sinder\u00a0BP, et\u00a0al. Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int. 2014;25(8):2097\u2013107.","journal-title":"Osteoporos Int"},{"key":"810_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","volume":"124","author":"M Cardinal","year":"2019","unstructured":"Cardinal\u00a0M, et\u00a0al. Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta. Bone. 2019;124:137\u201347.","journal-title":"Bone"},{"key":"810_CR20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","volume":"66","author":"A Roschger","year":"2014","unstructured":"Roschger\u00a0A, et\u00a0al. Effect of sclerostin antibody treatment in a\u00a0mouse model of severe osteogenesis imperfecta. Bone. 2014;66:182\u20138.","journal-title":"Bone"},{"issue":"7","key":"810_CR21","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux\u00a0FH, et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis Imperfecta: results of a\u00a0randomized phase 2a trial. J\u00a0Bone Miner Res. 2017;32(7):1496\u2013504.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"810_CR22","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1172\/JCI83731","volume":"127","author":"L Seefried","year":"2017","unstructured":"Seefried\u00a0L, et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J\u00a0Clin Invest. 2017;127(6):2148\u201358.","journal-title":"J Clin Invest"},{"key":"810_CR23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s10354-019-00732-2","volume":"170","author":"A Raimann","year":"2020","unstructured":"Raimann\u00a0A, Mindler\u00a0G, Kocijan\u00a0R, Bekes\u00a0K, Zwerina\u00a0J, Haeusler\u00a0G, et al. Multidisciplinary patient care in X\u2011linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr. 2020;170:116\u201323.","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"810_CR24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che\u00a0H, et al. Impaired quality of life in adults with X\u2011linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325\u201333.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"810_CR25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar\u00a0A, et al. The lifelong impact of X\u2011linked hypophosphatemia: results from a\u00a0burden of disease survey. J\u00a0Endocr Soc. 2019;3(7):1321\u201334.","journal-title":"J Endocr Soc"},{"issue":"5","key":"810_CR26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher\u00a0D, et al. Outcome of adult patients with X\u2011linked hypophosphatemia caused by PHEX gene mutations. J\u00a0Inherit Metab Dis. 2018;41(5):865\u201376.","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"810_CR27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner\u00a0D, et al. Clinical practice recommendations for the diagnosis and management of X\u2011linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435\u201355.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"810_CR28","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor\u00a0J, et al. Conventional therapy in adults with X\u2011linked hypophosphatemia: effects on enthesopathy and dental disease. J\u00a0Clin Endocrinol Metab. 2015;100(10):3625\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"810_CR29","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter\u00a0TO, et al. A clinician\u2019s guide to X\u2011linked hypophosphatemia. J\u00a0Bone Miner Res. 2011;26(7):1381\u20138.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"810_CR30","doi-asserted-by":"crossref","first-page":"107556","DOI":"10.1016\/j.jsb.2020.107556","volume":"211","author":"N Fratzl-Zelman","year":"2020","unstructured":"Fratzl-Zelman\u00a0N, et al. Alterations of bone material properties in adult patients with X\u2011linked hypophosphatemia (XLH). J\u00a0Struct Biol. 2020;211(3):107556.","journal-title":"J Struct Biol"},{"key":"810_CR31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2020.00338","volume":"11","author":"A Schindeler","year":"2020","unstructured":"Schindeler\u00a0A, Biggin\u00a0A, Munns\u00a0CF. Clinical evidence for the benefits of burosumab therapy for X\u2011linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol (Lausanne). 2020;11:338.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10189","key":"810_CR32","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel\u00a0EA, et al. Burosumab versus conventional therapy in children with X\u2011linked hypophosphataemia: a\u00a0randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416\u201327.","journal-title":"Lancet"},{"issue":"8","key":"810_CR33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna\u00a0KL, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X\u2011linked hypophosphatemia: week 24 primary analysis. J\u00a0Bone Miner Res. 2018;33(8):1383\u201393.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"810_CR34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale\u00a0AA, et al. Continued beneficial effects of burosumab in adults with X\u2011linked hypophosphatemia: results from a\u00a024-week treatment continuation period after a\u00a024-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105(3):271\u201384.","journal-title":"Calcif Tissue Int"},{"key":"810_CR35","volume-title":"Alkaline phosphatase","author":"D Lowe","year":"2020","unstructured":"Lowe\u00a0D, Sanvictores\u00a0T, John\u00a0S. Alkaline phosphatase. Treasure Island (FL): StatPearls Publishing LLC; 2020."},{"issue":"1","key":"810_CR36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.33176\/AACB-19-00031","volume":"41","author":"JP Salles","year":"2020","unstructured":"Salles\u00a0JP. Hypophosphatasia: biological and clinical aspects, avenues for therapy. Clin Biochem Rev. 2020;41(1):13\u201327.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"810_CR37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13023-020-01500-x","volume":"15","author":"M Vogt","year":"2020","unstructured":"Vogt\u00a0M, et al. Pediatric hypophosphatasia: lessons learned from a\u00a0retrospective single-center chart review of 50\u00a0children. Orphanet J Rare Dis. 2020;15(1):212.","journal-title":"Orphanet J Rare Dis"},{"key":"810_CR38","doi-asserted-by":"crossref","first-page":"1759720x1986399","DOI":"10.1177\/1759720X19863997","volume":"11","author":"V Choida","year":"2019","unstructured":"Choida\u00a0V, Bubbear\u00a0JS. Update on the management of hypophosphatasia. Ther Adv Musculoskelet Dis. 2019;11:1759720x19863997.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"810_CR39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","volume":"121","author":"PS Kishnani","year":"2019","unstructured":"Kishnani\u00a0PS, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149\u201362.","journal-title":"Bone"},{"issue":"2","key":"810_CR40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-017-4267-x","volume":"29","author":"SA Bowden","year":"2018","unstructured":"Bowden\u00a0SA, Adler\u00a0BH. Asfotase alfa treatment for 1\u00a0year in a\u00a016\u00a0year-old male with severe childhood hypophosphatasia. Osteoporos Int. 2018;29(2):511\u20135.","journal-title":"Osteoporos Int"},{"issue":"5","key":"810_CR41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1358\/dot.2016.52.5.2482878","volume":"52","author":"C Hofmann","year":"2016","unstructured":"Hofmann\u00a0C, Seefried\u00a0L, Jakob\u00a0F. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Drugs Today (Barc). 2016;52(5):271\u201385.","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"810_CR42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte\u00a0MP, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7\u00a0year outcomes of a\u00a0single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7(2):93\u2013105.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"810_CR43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","volume":"101","author":"MP Whyte","year":"2016","unstructured":"Whyte\u00a0MP, et\u00a0al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J\u00a0Clin Endocrinol Metab. 2016;101(1):334\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"810_CR44","doi-asserted-by":"crossref","first-page":"e10395","DOI":"10.1002\/jbm4.10395","volume":"4","author":"F Genest","year":"2020","unstructured":"Genest\u00a0F, et al. Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. JBMR Plus. 2020;4(9):e10395.","journal-title":"JBMR Plus"},{"issue":"11","key":"810_CR45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11926-018-0778-5","volume":"20","author":"S Simon","year":"2018","unstructured":"Simon\u00a0S, et\u00a0al. Hypophosphatasia: from diagnosis to treatment. Curr Rheumatol Rep. 2018;20(11):69.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"810_CR46","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.4158\/ACCR-2019-0143","volume":"5","author":"AL Magdaleno","year":"2019","unstructured":"Magdaleno\u00a0AL, et al. Adult-onset hypophosphatasia: before and after treatment with ASFOTASE ALFA. AACE Clin Case Rep. 2019;5(6):e344\u2013e8.","journal-title":"AACE Clin Case Rep"},{"issue":"5","key":"810_CR47","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jbm4.10052","volume":"2","author":"P Klidaras","year":"2018","unstructured":"Klidaras\u00a0P, et\u00a0al. Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy. JBMR Plus. 2018;2(5):304\u20137.","journal-title":"JBMR Plus"},{"key":"810_CR48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bone.2019.05.036","volume":"127","author":"T Rolvien","year":"2019","unstructured":"Rolvien\u00a0T, et al. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia. Bone. 2019;127:67\u201374.","journal-title":"Bone"},{"issue":"48","key":"810_CR49","doi-asserted-by":"crossref","first-page":"e13210","DOI":"10.1097\/MD.0000000000013210","volume":"97","author":"TQ Freitas","year":"2018","unstructured":"Freitas\u00a0TQ, Franco\u00a0AS, Pereira\u00a0RMR. Improvement of bone microarchitecture parameters after 12\u00a0months of treatment with asfotase alfa in adult patient with hypophosphatasia: case report. Medicine. 2018;97(48):e13210.","journal-title":"Medicine"},{"key":"810_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115664","author":"L Seefried","year":"2020","unstructured":"Seefried\u00a0L, et al. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone. 2020; https:\/\/doi.org\/10.1016\/j.bone.2020.115664.","journal-title":"Bone"},{"key":"810_CR51","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2019.02.025","volume":"122","author":"MP Whyte","year":"2019","unstructured":"Whyte\u00a0MP, et\u00a0al. No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Bone. 2019;122:231\u20136.","journal-title":"Bone"},{"issue":"9","key":"810_CR52","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00198-018-4613-7","volume":"29","author":"SA Bowden","year":"2018","unstructured":"Bowden\u00a0SA, Adler\u00a0BH. Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia. Osteoporos Int. 2018;29(9):2155\u20136.","journal-title":"Osteoporos Int"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-020-00810-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-020-00810-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-020-00810-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T20:13:25Z","timestamp":1617308005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-020-00810-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":52,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s10354-020-00810-w","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"12 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.\u00a0Kocijan previously received speaker fees, travel grants, research grants, fees for advisory-board and seminars from Alexion, UCB, Amgen and Kyowa Kirin. J.\u00a0Haschka previously received speaker fees and research grants from Alexion and Amgen. J.\u00a0Feurstein and J.\u00a0Zwerina declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}